TrialsgrambetaRCTs are beautiful

Fracture Prevention Trial

2001

Effect of Parathyroid Hormone (1-34) on Fractures

In 1,637 postmenopausal women with prior vertebral fractures, teriparatide 20 or 40 µg daily reduced new vertebral and non-vertebral fractures compared with placebo.

Result

Primary endpoint: New vertebral fracture

Vertebral fracture 5 % vs 14 %; RR 0.35 (20 µg), −65 %. Non-vertebral fragility −53 %.

Original publication
Subtopic
Teriparatide
Design
Double-blind RCT, median 21 mo (stopped early for rat osteosarcoma signal)
Relevance
Important: one of several pillars.
Source
Neer RM, et al. N Engl J Med. 2001;344(19):1434-1441.doi 10.1056/NEJM200105103441904

Discussion & critique

First anabolic agent for osteoporosis, reserved for very high fracture risk and mandates sequential antiresorptive therapy thereafter.